35 patents currently held
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2027. from the record
Of the 26 now held by other companies, 18 name Adneuris Therapeutics Inc. as their current owner, and 8 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Mar 2027
Next term end
28
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2027 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Jul 2039 · High confidence
Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels
US 7,718,640
Cited by 69 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Stable Formulation for Parenteral Administration of Tapentadol
US 11,013,701
A family of 58 related applications built on the 2021 grant. Protection runs to 2036.
Further Substituted Triazolo Quinoxaline Derivatives
US 10,981,918
The newest of the three, granted 2021. It anchors the portfolio to 2039, later than anything else here.
Formerly held, still cited
Notable
Ends Sep 2027 · High confidence
Cited by 84 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by GRT US Holding, Inc.
Also notable
Ends Aug 2031 · High confidence
Cited by 45 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Adneuris Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Tamper Resistant and Dose-Dumping Resistant Pharmaceutical Dosage Form (US 10,335,373) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 2 fees due Mar 3 to 15, 2027 · next Mar 3
- 2 fees due Apr 6 to 20, 2027 · next Apr 6
- 1 fee due Oct 21, 2027The maintenance fee for Substituted Pyrrolidine Amides I (US 10,626,106) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Further Substituted Triazolo Quinoxaline Derivatives (US 11,981,677) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- Nov 11Assignment recorded on US 11,344,512: Lange, Claudia to Grünenthal GmbH Recorded Nov 11, 2026, executed May 27, 2008. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76712, frame 682.
- Nov 11Assignment recorded on US 11,344,512: Rombout, Ferdinand to Grünenthal GmbH Recorded Nov 11, 2026, executed Apr 9, 2008. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76712, frame 723.
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
The 5 largest of its 28 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Process for the Preparation of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-PHENOL | 4 in force | to Jan 2037 |
| Further Substituted Triazolo Quinoxaline Derivatives | 2 in force | to Jul 2039 |
| Substituted Pyrrolidine Amides I | 2 in force | to Dec 2038 |
| Crystalline Naloxol-Peg Conjugate | 2 in force | to Apr 2032 |
| Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels | 2 in force | to May 2027 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,718,640 | Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels held by Grünenthal GmbH In force · High confidence | In force | High confidence | |
| US 8,338,395 | Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels held by Grünenthal GmbH In force · High confidence | In force | High confidence | |
| US 11,739,049 | Process for the Preparation of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-PROPYL)-PHENOL held by Grünenthal GmbH In force · High confidence | In force | High confidence | |
| US 8,939,748 | Method for the Production of a Form of Administration of a Medicament held by Grünenthal GmbH In force · High confidence | In force | High confidence | |
| US 8,088,322 | Method and Device for Ultrasound-Pressing a Tablet or a Multiparticulate Medicament In force · High confidence | In force | High confidence | |
| US 8,263,809 | Preparation of 3-[(1R,2R)-3-(DIMETHYLAMINO)-1ETHYL-2-Methylpropyl]PHENOL In force · High confidence | In force | High confidence | |
| US 8,383,152 | Pharmaceutical Dosage Form In force · High confidence | In force | High confidence | |
| US 8,134,032 | Crystalline Modifications of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-PROPYL)-PHENOL In force · High confidence | In force | High confidence | |
| US 8,877,974 | Process for the Preparation of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-PHENOL Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 9,579,285 | Preparation of a Powdery Pharmaceutical Composition by Means of an Extruder In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 26 patents in force now held by others · 250 patents ended · 11 applications pending · 231 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.